02 June 2026 : Clinical Research
Ciprofol-Esketamine Versus Ciprofol-Remifentanil in Hysteroscopic Endometrial Polypectomy: A Randomized Controlled Trial
Zhong Zhang ABC 1, Zhixu Wang BC 1, Wanwan Gong DEF 1, Wei Jiang AF 1*, Longjiao Zheng DEF 1, Zhiyang Yu AEF 1DOI: 10.12659/MSM.952468
Med Sci Monit 2026; 32:e952468
Table 3 Adverse events.
| Variable | CK (n=60) | CR (n=60) | χ2/t | P |
|---|---|---|---|---|
| Primary outcome | ||||
| Hypoxemia rate | 1 (1.7%) | 21 (35.0%) | 22.263 | < 0.001 |
| Secondary outcomes | ||||
| Body movement | 14 (23.3%) | 17 (28.3%) | 0.391 | 0.677 |
| Mental adverse reactions | 0 (0%) | 0 (0%) | 0.000 | 1.000 |
| PONV | 2 (3.3%) | 5 (8.3%) | 1.365 | 0.439 |
| Total incidence rate | 16 (26.7%) | 22 (36.7%) | 1.386 | 0.239 |
| Safety outcomes | ||||
| Hypertension | 1 (1.7%) | 0 (0%) | 1.008 | 0.315 |
| Hypotension | 10 (16.7%) | 20 (33.3%) | 4.444 | 0.035 |
| Tachycardia | 1 (1.7%) | 1 (1.7%) | 1.000 | 1.000 |
| Bradycardia | 0 (0%) | 0 (0%) | 0.000 | 1.000 |
| Total incidence rate | 12 (20.0%) | 21 (35.0%) | 5.264 | 0.098 |
| Vasoactive drugs | 1 (1.7%) | 1 (1.7%) | 0.000 | 1.000 |
| CK – ciprofol-esketamine regimen; CR – ciprofol-remifentanil regimen; PONV – postoperative nausea and vomiting. | ||||